Vitamin E dietary supplementation significantly affects multiple risk factors for cardiovascular disease in baboons

American Journal of Clinical Nutrition

Volumn 86, Issue 3, 2007, Pages 597-603

  Rainwater, David L ^a,b   Mahaney, Michael C ^a   VandeBerg, John L ^a,b   Xing, Li Wang ^a,c  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^b SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antioxidants; Apo A I; Apolipoprotein A I; Baboons; HDL; High density lipoprotein; Paraoxonase; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; FAT; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENIC DIET; BABOON; BLOOD SAMPLING; CALCULATION; CARDIOVASCULAR DISEASE; CORRELATION COEFFICIENT; DIET SUPPLEMENTATION; FEEDING; GENETIC ANALYSIS; GENETIC TRAIT; LIPOPROTEIN METABOLISM; NONHUMAN; OXIDATIVE STRESS; PEDIGREE; PROTEIN QUALITY; RISK FACTOR; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; VITAMIN BLOOD LEVEL;

PAPIO;

EID: 34548789039     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/86.3.597     Document Type: Article

References (52)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Navab M, Ananthramaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004;45:993-1007.
3. Morris CD, Carson S. Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003;139:56-70.
4. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003;361:2017-23.
5. Rogers J, Hixson JE. Baboons as an animal model for genetic studies of common human disease. Am J Hum Genet 1997;61:489-93.
6. Wang XL, Rainwater DL, Mahaney MC, Stocker R. Cosupplementation with vitamin E and coenzyme Q10 reduces circulating markers of inflammation in baboons. Am J Clin Nutr 2004;80:649-55.
7. McGill HC Jr, McMahan CA, Mott GE, Marinez YN, Kuehl TJ. Effects of selective breeding on the cholesterolemic responses to dietary saturated fat and cholesterol in baboons. Arteriosclerosis 1988;8:33-9.
8. Kushwaha RS, Rice KS, Lewis DS, McGill HC Jr, Carey KD. The role of cholesterol absorption and hepatic cholesterol content in high and low responses to dietary cholesterol and fat in pedigreed baboons (Papio species). Metabolism 1993;42:714-22.
9. Singh ATK, Rainwater DL, Kammerer CM, et al. Dietary and genetic effects on LDL size measures in baboons. Arterioscler Thromb Vasc Biol 1996;16:1448-53.
10. Cheng M-L, Woodford SC, Hilburn JL, VandeBerg JL. A novel system for storage of sera frozen in small aliquots. J Biochem Biophys Methods 1986;13:47-51.
11. Lipid Research Clinics Program. Manual of laboratory operations. Volume 1: lipid and lipoprotein analysis. Washington, DC: US Government Printing Office, 1974. (DHEW publication NIH 75-628).
12. Nichols AV, Krauss RM, Musliner TA. Nondenaturing polyacrylamide gradient gel electrophoresis. Meth Enzymol 1986;128:417-31.
13. Rainwater DL, Moore PH Jr, Shelledy WR, Dyer TD, Slifer SH. Characterization of a composite gradient gel for the electrophoretic separation of lipoproteins. J Lipid Res 1997;38:1261-6.
14. Rainwater DL, Moore PH Jr, Gamboa IO. Improved method for making nondenaturing composite gradient gels for the electrophoretic separation of lipoproteins. J Lipid Res 2004;45:773-5.
15. Richter RJ, Jampsa RL, Jarvik GP, Costa LG, Furlong CE. Determination of paraoxonase 1 status and genotypes at specific polymorphic sites. Curr Protocols Toxicol 2004;4:4.12.1-19.
16. Lange K, Weeks D, Boehnke M. Programs for pedigree analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol 1988;5:471-2.
17. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 1998;62:1198-211.
18. Singh U, Devaraj S, Jialal I. Vitamin E, oxidative stress, and inflammation. Annu Rev Nutr 2005;25:151-74.
19. Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 2001;38:606-11.
20. Chao JCJ, Yuan M-D, Chen P-Y, Chien S-W. Vitamin C and E supplements improve the impaired antioxidant status and decrease plasma lipid peroxides in hemodialysis patients. J Nutr Biochem 2002;13:653-63.
21. Leeson CP, Mann A, Kattenhorn M, Deanfield JE, Lucas A, Muller DP. Plasma vitamin E, total antioxidant status and vascular function in young adults. Eur J Clin Invest 2002;32:889-94.
22. Stephensen CB, Marquis GS, Jacob RA, Kruzich LA, Douglas SD, Wilson CM. Vitamins C and E in adolescents and young adults with HIV infection. Am J Clin Nutr 2006;83:870-9.
23. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004;109(suppl):III2-7.
24. Hodis HN, Mack WJ, LaBree L, et al. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 2002;106:1453-9.
25. Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 2005;16:393-9.
26. Jeon S-M, Park YB, Kwon O-S, et al. Vitamin E supplementation alters HDL-cholesterol concentration and paraoxonase activity in rabbits fed high-cholesterol diet: comparison with probucol. J Biochem Mol Toxicol 2005;19:336-46.
27. Jarvik GP, Tsai NT, McKinstry LA, et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002;22:1329-33.
28. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
29. 3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation 1992;85:22-9.
30. Drexel H, Amann FW, Beran J, et al. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation 1994;90:2230-5.
31. 2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) report. Arterioscler Thromb Vasc Biol 1995;15:1049-56.
32. 3 subfractions with ischemic heart disease in men - prospective results from the Quebec cardiovascular study. Arterioscler Thromb Vasc Biol 1997;17:1098-105.
33. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998;18:1046-53.
34. Colhoun HM, Otvos JD, Rubens MB, Taskinen MR, Underwood SR, Fuller JH. Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes. Diabetes 2002;51:1949-56.
35. Moss AJ, Goldstein RE, Marder VJ, et al. Thrombogenic factors and recurrent coronary events. Circulation 1999;99:2517-22.
36. Sweetnam PM, Bolton CH, Downs LG, et al. Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly Study. Eur J Clin Invest 2000;30:947-56.
37. Luc G, Bard JM, Ferrieres J, et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 2002;22:1155-61.
38. Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006;259:481-92.
39. Aldred S, Sozzi T, Mudway I, et al. Alpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects. Proteomics 2006;6:1695-703.
40. Westman J, Roobol C, Carlson LA, Wulfert E. In vitro reverse cholesterol transport from THP-1-derived macrophage-like cells with synthetic HDL particles consisting of proapolipoprotein A1 or apolipoprotein A1 and phosphatidylcholine. Scand J Clin Lab Invest 1995;55:23-33.
41. Nanjee MN, Cooke CJ, Garvin R, et al. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res 2001;42:1586-93.
42. Garner B, Witting PK, Waldeck AR, Christison JK, Raftery M, Stocker R. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. J Biol Chem 1998;273:6080-7.
43. Wang XL, Dudman NPB, Wang J, Wilcken DEL. Mechanisms responsible for increasing immunoreactivity of apolipoprotein A-I with storage: the role of oxidation. Clin Chem 1989;35:2082-6.
44. Jia Z, Natarajan P, Forte TM, Bielicki JK. Thiol-bearing synthetic peptides retain the antioxidant activity of apolipoprotein A-I(Milano). Biochem Biophys Res Commun 2002;297:206-13.
45. Nguyen SD, Jeong TS, Sok DE. Apolipoprotein A-I-mimetic peptides with antioxidant actions. Arch Biochem Biophys 2006;451:34-42.
46. Rainwater DL, Kammerer CM, Carey KD, et al. Genetic determination of HDL variation and response to diet in baboons. Atherosclerosis 2002;161:335-43.
47. Jarvik GP, Hatsukami TS, Carlson C, et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol 2003;23:1465-71.
48. Rainwater DL, Mahaney MC, Wang XL, Rogers J, Cox LA, VandeBerg JL. Determinants of variation in serum paraoxonase enzyme activity in baboons. J Lipid Res 2005;46:1450-6.
49. Dutta A, Dutta SK. Vitamin E and its role in the prevention of atherosclerosis and carcinogenesis: a review. J Am Coll Nutr 2003;22:258-68.
50. Tucker JM, Townsend DM. Alpha-tocopherol: roles in prevention and therapy of human disease. Biomed Pharmacother 2005;59:380-7.
51. Azzi A, Ricciarelli R, Zingg JM. Non-antioxidant molecular functions of alpha-tocopherol (vitamin E). FEBS Lett 2002;519:8-10.
52. Teupser D, Thiery J, Seidel D. Alpha-tocopherol down-regulates scavenger receptor activity in macrophages. Atherosclerosis 1999;144:109-15.